ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Left ventricular ejection fraction and myocardial fibrosis in sudden cardiac death.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histopathological Profile of the Heart in Sudden Death: Forensic Perspectives on Cardiac and Noncardiac Mechanisms.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsLeft ventricular ejection fraction (LVEF) remains the key determinant in the evaluation for the risk of sudden cardiac death (SCD). Myocardial fibrosis has gained increasingly more interest in the context of various myocardial diseases. We determined the spectrum of LVEF and evaluated the association between myocardial fibrosis and pre-SCD LVEF in a population-based SCD cohort. METHODS AND
resultsThe Fingesture study and clinical data have been collected from consecutive autopsy-verified SCD victims from Northern Finland between 1998 and 2017 (n = 5869). The cause of death was verified in medicolegal autopsy in all subjects. Electronic health records were used to identify those with pre-mortem echocardiography data. The extent of myocardial fibrosis at autopsy was characterized macroscopically and from histology samples. The LVEF recorded median 2 years (interquartile range 1-5) prior to SCD was evaluated in 716 SCD subjects. Proportional LVEF values were as follows: 62.7% (n = 449) normal LVEF (≥50%), 21.9% (n = 157) mildly reduced LVEF (36-49%), and 15.4% (n = 110) severely reduced LVEF (≤35%). At autopsy 19.6% (n = 140) had substantial, 53.8% (n = 386) moderate, and 22.1% (n = 158) mild fibrosis, and 4.5% (n = 32) had no myocardial fibrosis. The extent of myocardial fibrosis and LVEF had poor correlation (Spearman's ρ 0.21, CI 0.141-0.285, P < 0.001). Only 21.4% of those with substantial fibrosis at autopsy had LVEF ≤35%.
conclusionThe proportion of SCD subjects with LVEF ≤35% is low, and the prevalence of myocardial fibrosis is high. The LVEF has a weak correlation with the extent of myocardial fibrosis. Our study suggests that LVEF is a poor surrogate of myocardial fibrosis in SCD victims.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.